Israeli additive manufacturing company Nano Dimension has signed a non-binding letter of intent to merge with AI health diagnostics firm Infinite Epigenetics in a deal valued at $890 million. If completed, the combined company will be renamed Infinite Epigenetics with the ticker IEAI. Infinite Epigenetics specializes in epigenetic analysis, reading over 1 million epigenetic signals in a single test using proprietary AI models for disease detection and health assessment. The company integrates CLIA-certified lab TruDiagnostic and consumer longevity health business Tally Health, having processed over 120,000 epigenetic samples since 2020. Nano Dimension stated it selected this deal after months of reviewing approximately 20 candidate opportunities, aiming to provide shareholders with exposure to the medical diagnostics market.